Path
Productumnomen | Citrate Tofacitinib |
Synonyma | (3R,4R) -1-(Cyanoacetyl) -4-methyl-N-methyl-N-1H-pyrrolo[2,3-d] pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3 -propanetricarboxylate;CP 690500-10;CP 690550-10;(3R,4R) -4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino) |
CAS Non. | 540737-29-9 |
Aspectus | Off album in cerussa |
Formulae hypotheticae | C16H20N6OC6H8O7 |
M. Pondus | 504.50 |
Applicationem | Pharmaceutical gradus seu investigationis propositum |
stipare | Quod per petitio tua |
Repono | Serva in stricta, levis vasis repugnans in loco frigido |
Citrate Tofacitinib (CAS #540737-29-9) | ||
ITEMS | SIGNA | Effectus |
Aspectus | Off album in cerussa | Off album pulveris |
Lepidium sativum | HPLC;IR;HNMR | Obsequitur |
Solubilitas | Solutum in DMSO ad 100mg/ml, in ethanolo pessime solutum, in aqua parce solutum etc. | Obsequitur |
Damnum in Siccatio | ≤0.5% | 0.12% |
Reliqua ignitio | ≤0.1% | 0.05% |
Metalla gravis | ≤10ppm | Obsequitur |
Substantiae cognatae | Diastereomer (RS+SR) ≤0.1% Una immunditia ≤0.15% Totalis immunditias ≤1.0% | 0.05% 0.14% 0.18% |
Enantiomorphism Isomers | ≤0.2% | Obsequitur |
RELICTUM Solvents | Ethanol ≤5000ppm Methanol ≤3000ppm Toluene ≤890ppm | Obsequitur |
Citare Content | 36.2%~40% | 37.8% |
Puritas | ≥99.0% | 99.38% |
Assay | 60.68%~63.16% of Tofacitinib INN 98%~ 102% de Tofacitinib Citrate INN | 62.04%
99.12% |
Conclusio |
Company Information
√ Procuratio accumsan plena experientia in technicis et technicis peritissimis sectatoribus; √ Quality is always our top consideration, Strict QC system; √ 11 annos periti quadrigis venditio educendi; √ Independentes R&D lab; √ Duae officinae GMP terminus signati longi sunt; √ Divites copiarum otiosorum officinarum copia pro project nativus; √ High Efficiency working team with consistent path.Epistulam tuam hic scribe et mitte nobis